Join the Ulcerative Colitis group to help and get support from people like you.
Ulcerative Colitis News (Page 2)
Related terms: Colitis, Ulcerative, UC, Colitis Ulcerosa
FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced ...
Over 100,000 U.S. Youth Battle Inflammatory Bowel Disease
MONDAY, Dec.2, 2024 – Cases of inflammatory bowel disease (IBD) are rising at an alarming rate among young Americans, a new study reveals. "Prevalence rates [are] among the highest reported...
Estimated 100,429 U.S. Youth Living With Pediatric Inflammatory Bowel Disease
FRIDAY, Nov. 22, 2024 – An estimated 100,429 youth are living with pediatric inflammatory bowel disease (PIBD) in the United States, according to a research letter published online Nov. 20 in...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of Selarsdi (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab)
REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
People With Inflammatory Bowel Disease Face Barriers to Health Care
MONDAY, Oct. 21, 2024 – Patients with inflammatory bowel disease (IBD) continue to experience barriers to health care access and treatment and financial struggles, according to a study published...
Researchers Find Biomarker Tied to Severity of Ulcerative Colitis
FRIDAY, Oct. 18, 2024 – For patients with ulcerative colitis, the HLA-DRB1*01:03 allele is associated with severe ulcerative colitis, according to a research letter published online Oct. 15 in the...
FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara
RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
Crohn's, Colitis Care Take Big Financial Toll on Patients
THURSDAY, Oct. 10, 2024 – Inflammatory bowel conditions such as Crohn’s disease and colitis cause intense financial pressure as well as physical distress, a new study shows. More than 40% of people w...
Anti-TL1A Monoclonal Antibody, Tulisokibart, Aids Ulcerative Colitis
FRIDAY, Oct. 4, 2024 – Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara
September 30, 2024 – Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic...
Tremfya (guselkumab) Receives U.S. FDA Approval for Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, Pa. (September 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya® (guselkumab) for the treatment of adults with m...
Treatment Could Be New Option for People Battling Ulcerative Colitis
FRIDAY, Sept. 27, 2024 – An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The...
FDA Approves Tremfya for Ulcerative Colitis
MONDAY, Sept. 16, 2024 – The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis. Tremfya is the...
RSV Infection With Inflammatory Bowel Disease Ups Risk for Hospitalization
WEDNESDAY, Aug. 28, 2024 – Adult patients with inflammatory bowel disease (IBD) and respiratory syncytial virus (RSV) infection have an increased risk for hospitalization, according to a study...
FDA Approves Skyrizi (risankizumab-rzaa) for Ulcerative Colitis
NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for adults with moderately ...
Further information
Related condition support groups
Ulcerative Colitis - Active, Colitis
Related drug support groups
Humira, clonidine, hydrocortisone, Entyvio, Stelara, Remicade, Xeljanz, Skyrizi, dexamethasone, adalimumab, budesonide, ustekinumab, Tremfya